The most advanced testing service for testicular cancer ever available has been launched in the UK by EDX Medical.
The non-invasive testing service has exceptional sensitivity in a broad range of men across ethnicities and ages and also detects cancer recurrences with ultra-high accuracy.
The service comprises the assessment of a range of biomarkers that can detect very early signs of the disease, enabling healthcare professionals to confirm presence or absence of testicular cancer in a small blood sample. Testicular can be treated very successfully if caught early.
Those who have been diagnosed with testicular cancer can also be repeatedly checked with EDX Medical’s TC 100 service which has demonstrated 100% success rates in post diagnosis surveillance of thousands of patients.
The first two patients referred to the TC100 service by their doctors, yielded data that confirmed, with 99% accuracy, that one young man was in fact completely clear of testicular cancer, whilst in the second case, the presence of testicular cancer was detected and confirmed in a subsequent scan, enabling treatment to commence rapidly.
Testicular cancer is now the most common form of cancer among young men. There are around 2,500 new cases of testicular cancer in the UK every year and 50,000 survivors of testicular cancer who could benefit from accurate post-treatment monitoring. Survival rates for testicular cancer are in excess of 90% if the disease is identified and treated early.
More than 30 clinical study reports have confirmed the accuracy and clinical usefulness of the proprietary micro-RNA biomarker included in the TC100 service, supporting its use alone or in combination with established biomarkers used by the NHS in primary diagnosis, early detection, metastatic disease and recurrence of both seminoma and non-seminoma testicular cancer.
Professor Sir Chris Evans, OBE, founder of EDX Medical Group plc, commented: “The service that is now available to young men is the most accurate in the world and targets a wide range of males from teenagers to men in their forties who can benefit from this type of testing by giving them the very best information possible. As we have seen with other types of cancer, early testing can prove invaluable and lifesaving.”
One of the first doctors in the UK who used the TC100 service, Dr Anand Sharma, consultant oncologist at the Mount Vernon Cancer Centre, Middlesex, commented: “The accuracy was unprecedented, and the rapid laboratory service enabled me to advise the patient swiftly and to give him full confidence in the result of the testing.”
Leading actor and cancer awareness campaigner, Colin McFarlane, commented: “Whilst prostate cancer is the commonest cancer in us older guys, as I well know, it is testicular cancer that’s the commonest in younger men. Diagnosis of testicular cancer – earlier the better – can prevent major fertility issues or death and can lead to a complete recovery from cancer for these boys. To have such an amazingly accurate testing service available as this EDX TC100 for young men is fantastic.”
Dermot Murnaghan, television presenter, said: “I know only too well from my own prostate diagnosis the serious threat that men face from prostate and testicular cancer. I know of no-one who has been diagnosed with either of these cancers who does not wish they had been in a position to get tested much earlier and more accurately. When it comes to testicular cancer, it is in the interest of young men in particular to get checked out as soon as they can. A testing service with this amazing accuracy is a real asset to doctors.”
Dr Mike Hudson, CEO, EDX Medical, said: “The highly sensitive service includes and significantly enhances the current confirmatory NHS biomarkers. All healthcare professionals in the UK can access the service to help them quickly and accurately identify the early emergence of testicular cancer, as well as to detect any residual disease or recurrence in patients under surveillance following treatment. We’re proud to be launching the TC100 service which we believe sets a new standard for the early detection, and hence better outcomes, for testicular cancer patients.”
About the EDX Medical TC 100 testing service
The EDX Medical TC100 service is based on a simple blood sample which is taken by a health professional and sent for laboratory analysis.
Multiple specific tumour biomarkers are analysed in the testing process and a detailed report is prepared for clinicians to help determine the presence or absence of disease and to help guide treatment if required.
The TC 100 testing service includes unique micro-RNA biomarker reporting alongside the classic three serum biomarkers AFP – Alpha-fetoprotein, HCG – Human Chorionic Gonadotrophin and LDH – Lactate Dehydrogenase, currently included in the NHS testicular cancer treatment pathway. The complete testing service is available from £875. Read more about our Testicular Cancer Testing.
